Trial Profile
Bone metabolic markers, TRAP, and Zometa's effect on bone metastasis due to lung cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2018
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Liver cancer
- Focus Therapeutic Use
- 14 Apr 2011 Planned end date changed from 1 Dec 2008 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 14 Apr 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 19 Jan 2010 Actual patient number (28) added as reported by ClinicalTrials.gov.